Sumitomo Dainippon Pharma Co Ltd (4506):企業の財務・戦略的SWOT分析

◆英語タイトル:Sumitomo Dainippon Pharma Co Ltd (4506) - Financial and Strategic SWOT Analysis Review
◆商品コード:DATA904C4822
◆発行会社(調査会社):GlobalData
◆発行日:2018年8月
◆ページ数:63
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:日本
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD125 ⇒換算¥18,500見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD375 ⇒換算¥55,500見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Sumitomo Dainippon Pharma Co Ltd (4506) – Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.
The profile contains critical company information including:

- Business description – A detailed description of the company’s operations and business divisions.
- Corporate strategy – Analyst’s summarization of the company’s business strategy.
- SWOT Analysis – A detailed analysis of the company’s strengths, weakness, opportunities and threats.
- Company history – Progression of key events associated with the company.
- Major products and services – A list of major products, services and brands of the company.
- Key competitors – A list of key competitors to the company.
- Key employees – A list of the key executives of the company.
- Executive biographies – A brief summary of the executives’ employment history.
- Key operational heads – A list of personnel heading key departments/functions.
- Important locations and subsidiaries – A list and contact details of key locations and subsidiaries of the company.
- Key manufacturing facilities – A list of key manufacturing facilities of the company.
- Detailed financial ratios for the past five years – The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
- Interim ratios for the last five interim periods – The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.

Highlights

Sumitomo Dainippon Pharma Co Ltd (Sumitomo Dainippon), a subsidiary of Sumitomo Chemical Co., Ltd, develops manufacturers, purchases, sells, imports and exports pharmaceutical products. The company focuses on major therapeutic areas which include central nervous system (CNS), cardiovascular, diabetes, oncology, respiratory psychiatry and neurology and infectious diseases. It also offers veterinary products, research materials, food additives, chemical product materials, food ingredients, diagnostic agents, cosmetic materials and other products. Sumitomo Dainippon has research laboratories, manufacturing and distribution facilities in Japan. The company operates through subsidiaries and offices in the North America, Europe and Asia Pacific. Sumitomo Dainippon is headquartered in Chuo-ku, Osaka, Japan.

Sumitomo Dainippon Pharma Co Ltd Key Recent Developments

Jul 30,2018: Kyoto University Hospital and the Center for iPS Cell Research and Application (CiRA) to begin physician-initiated clinical trials for parkinson’s disease
Jul 27,2018: Sumitomo Dainippon Pharma provides summary of consolidated financial results for the first quarter of the year ending March 31, 2019
Jul 17,2018: Sumitomo Dainippon Pharma Listed in FTSE4Good Index Series of Socially Responsible Investment and FTSE Blossom Japan Index
Jun 28,2018: Sumitomo Dainippon Pharma Contributes to Northern Osaka Earthquake Relief Efforts in Japan
Jun 15,2018: Sumitomo Dainippon Pharma Announces Management Changes

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.

Understand and respond to your competitors’ business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.
- The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.

Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.
- Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.

Scout for potential investments and acquisition targets, with detailed insight into the companies’ strategic, financial and operational performance.
- Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.

Gain key insights into the company for academic or business research.
- Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.

Note: Some sections may be missing if data is unavailable for the company

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
Section 1 – About the Company 6
Sumitomo Dainippon Pharma Co Ltd – Key Facts 6
Sumitomo Dainippon Pharma Co Ltd – Key Employees 7
Sumitomo Dainippon Pharma Co Ltd – Key Employee Biographies 9
Sumitomo Dainippon Pharma Co Ltd – Major Products and Services 10
Sumitomo Dainippon Pharma Co Ltd – History 12
Sumitomo Dainippon Pharma Co Ltd – Company Statement 20
Sumitomo Dainippon Pharma Co Ltd – Locations And Subsidiaries 21
Head Office 21
Other Locations & Subsidiaries 21
Section 2 – Company Analysis 24
Company Overview 24
Sumitomo Dainippon Pharma Co Ltd – Business Description 25
Business Segment: Other 25
Overview 25
Performance 25
Business Segment: Pharmaceuticals 25
Overview 25
Performance 25
Geographical Segment: Japan 25
Performance 25
Geographical Segment: North America 26
Performance 26
Geographical Segment: Others 26
Performance 26
R&D Overview 26
Sumitomo Dainippon Pharma Co Ltd – Corporate Strategy 27
Sumitomo Dainippon Pharma Co Ltd – SWOT Analysis 28
SWOT Analysis – Overview 28
Sumitomo Dainippon Pharma Co Ltd – Strengths 28
Sumitomo Dainippon Pharma Co Ltd – Weaknesses 29
Sumitomo Dainippon Pharma Co Ltd – Opportunities 30
Sumitomo Dainippon Pharma Co Ltd – Threats 31
Sumitomo Dainippon Pharma Co Ltd – Key Competitors 32
Section 3 – Company Financial Ratios 33
Financial Ratios – Capital Market Ratios 33
Financial Ratios – Annual Ratios 34
Performance Chart 37
Financial Performance 37
Financial Ratios – Interim Ratios 38
Financial Ratios – Ratio Charts 39
Section 4 – Company’s Lifesciences Financial Deals and Alliances 40
Sumitomo Dainippon Pharma Co Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 40
Sumitomo Dainippon Pharma Co Ltd, Pharmaceuticals & Healthcare, Deals By Type, 2012 to YTD 2018 41
Sumitomo Dainippon Pharma Co Ltd, Recent Deals Summary 42
Section 5 – Company’s Recent Developments 43
Jul 30, 2018: Kyoto University Hospital and the Center for iPS Cell Research and Application (CiRA) to begin physician-initiated clinical trials for parkinson’s disease 43
Jul 27, 2018: Sumitomo Dainippon Pharma provides summary of consolidated financial results for the first quarter of the year ending March 31, 2019 44
Jul 17, 2018: Sumitomo Dainippon Pharma Listed in FTSE4Good Index Series of Socially Responsible Investment and FTSE Blossom Japan Index 47
Jun 28, 2018: Sumitomo Dainippon Pharma Contributes to Northern Osaka Earthquake Relief Efforts in Japan 48
May 31, 2018: Sumitomo Dainippon Pharma Joins IFPMA as New Member[TOPC : Pharma - Sumitomo Dainippon Pharma Co Ltd] 49
May 11, 2018: Sumitomo Dainippon Pharma announces Changes in Board of Directors, Audit & Supervisory Board and Other Key Positions 50
May 11, 2018: Sumitomo Dainippon Pharma: Summary of Consolidated Financial Results for the Year Ended March 31, 2018 51
Apr 03, 2018: Sumitomo Dainippon Pharma Chooses Cytonome’s GigaSort Cell Sorting Technology for Cell Bioprocessing 56
Mar 01, 2018: Sumitomo Dainippon Pharma Completes Manufacturing Plant for Regenerative Medicine & Cell Therapy 57
Mar 01, 2018: Sumitomo Dainippon Pharma Completes Manufacturing Plant for Regenerative Medicine & Cell Therapy 58
Section 6 – Appendix 59
Methodology 59
Ratio Definitions 59
About GlobalData 63
Contact Us 63
Disclaimer 63

List of Tables
Sumitomo Dainippon Pharma Co Ltd, Key Facts 6
Sumitomo Dainippon Pharma Co Ltd, Key Employees 7
Sumitomo Dainippon Pharma Co Ltd, Key Employee Biographies 9
Sumitomo Dainippon Pharma Co Ltd, Major Products and Services 10
Sumitomo Dainippon Pharma Co Ltd, History 12
Sumitomo Dainippon Pharma Co Ltd, Other Locations 21
Sumitomo Dainippon Pharma Co Ltd, Subsidiaries 22
Sumitomo Dainippon Pharma Co Ltd, Key Competitors 32
Sumitomo Dainippon Pharma Co Ltd, Ratios based on current share price 33
Sumitomo Dainippon Pharma Co Ltd, Annual Ratios 34
Sumitomo Dainippon Pharma Co Ltd, Annual Ratios (Cont...1) 35
Sumitomo Dainippon Pharma Co Ltd, Annual Ratios (Cont...2) 36
Sumitomo Dainippon Pharma Co Ltd, Interim Ratios 38
Sumitomo Dainippon Pharma Co Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 40
Sumitomo Dainippon Pharma Co Ltd, Pharmaceuticals & Healthcare, Deals By Type, 2012 to YTD 2018 41
Sumitomo Dainippon Pharma Co Ltd, Recent Deals Summary 42
Currency Codes 59
Capital Market Ratios 59
Equity Ratios 60
Profitability Ratios 60
Cost Ratios 61
Liquidity Ratios 61
Leverage Ratios 62
Efficiency Ratios 62

List of Figures
Sumitomo Dainippon Pharma Co Ltd, Performance Chart (2014 - 2018) 37
Sumitomo Dainippon Pharma Co Ltd, Ratio Charts 39
Sumitomo Dainippon Pharma Co Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 40
Sumitomo Dainippon Pharma Co Ltd, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 41

★海外企業調査レポート[Sumitomo Dainippon Pharma Co Ltd (4506):企業の財務・戦略的SWOT分析]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • HICL Infrastructure Co Ltd:企業のM&A・事業提携・投資動向
    HICL Infrastructure Co Ltd - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's HICL Infrastructure Co Ltd Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acqui …
  • Avingtrans Plc (AVG):企業の財務・戦略的SWOT分析
    Avingtrans Plc (AVG) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and …
  • Indianapolis Power & Light Co-エネルギー分野:企業M&A・提携分析
    Summary Indianapolis Power & Light Co (IPL), a subsidiary of IPALCO Enterprises Inc, is an integrated electric utility. The company generates, transmits, distributes, and sells electric energy. It produces electricity from coal, oil, and natural gas sources. IPL owns and operates power plants in Ind …
  • The Timken Company
    The Timken Company - Strategy, SWOT and Corporate Finance Report Summary The Timken Company - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and …
  • Rashtriya Chemicals and Fertilizers Ltd (RCF):企業の財務・戦略的SWOT分析
    Summary Rashtriya Chemicals and Fertilizers Ltd (RCFL) is a chemical company that manufactures and markets fertilizers and industrial chemicals. The company offers industrial chemicals include methanol, mono methylamine, strong nitric acid, dilute nitric acid, sulphuric acid, sodium nitrite, anhydro …
  • Hatch Ltd:企業の戦略的SWOT分析
    Hatch Ltd - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and services. Th …
  • CHS Inc (CHSCP):企業の財務・戦略的SWOT分析
    CHS Inc (CHSCP) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the p …
  • National Bank of Canada:企業のM&A・事業提携・投資動向
    National Bank of Canada - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's National Bank of Canada Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisition …
  • B&M European Value Retail S.A.:戦略・SWOT・企業財務分析
    B&M European Value Retail S.A. - Strategy, SWOT and Corporate Finance Report Summary B&M European Value Retail S.A. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product a …
  • Soitec SA (SOI):企業の財務・戦略的SWOT分析
    Soitec SA (SOI) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the p …
  • Charles River Laboratories International, Inc.:企業の戦略・SWOT・財務情報
    Charles River Laboratories International, Inc. - Strategy, SWOT and Corporate Finance Report Summary Charles River Laboratories International, Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, ope …
  • Femasys Inc:医療機器:M&Aディール及び事業提携情報
    Summary Femasys Inc (Femasys) is a medical device company that develops and manufactures medical device solutions for women’s healthcare. The company offers non-surgical female sterilization devices, and devices for the diagnosis of infertility, and cervical cancer diagnosis. Its products include fe …
  • Nuevolution AS-製薬・医療分野:企業M&A・提携分析
    Summary Nuevolution A/S (Nuevolution), a subsidiary of Nuevolution AB, is a biopharmaceutical company that develops treatments for cancer and chronic inflammatory diseases. It focuses on developing drugs for the treatment of chronic inflammatory diseases such as rheumatoid arthritis, psoriasis; onco …
  • NorgesGruppen ASA:企業の戦略的SWOT分析
    NorgesGruppen ASA - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and serv …
  • Abercrombie & Fitch Co.:企業の戦略・SWOT・財務情報
    Abercrombie & Fitch Co. - Strategy, SWOT and Corporate Finance Report Summary Abercrombie & Fitch Co. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service off …
  • Aerostar S.A.:企業の戦略・SWOT・財務分析
    Aerostar S.A. - Strategy, SWOT and Corporate Finance Report Summary Aerostar S.A. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate …
  • Northwell Health Inc:製薬・医療:M&Aディール及び事業提携情報
    Summary Northwell Health Inc (Northwell Health), formerly North Shore - Long Island Jewish Health System Inc, is a home health care service provider. The center offers services in the areas of anesthesiology and pain management, brain and nerve, cancer and blood disorder, child and teen health, diab …
  • Reliance Infrastructure Ltd.:企業の戦略・SWOT・財務情報
    Reliance Infrastructure Ltd. - Strategy, SWOT and Corporate Finance Report Summary Reliance Infrastructure Ltd. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and s …
  • Urban One Inc (UONEK):企業の財務・戦略的SWOT分析
    Urban One Inc (UONEK) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and …
  • Minerals Technologies Inc (MTX):企業の財務・戦略的SWOT分析
    Minerals Technologies Inc (MTX) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weak …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆